Literature DB >> 26304221

Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components.

Isabella Bertoldi1, Agnese Faleri1, Barbara Galli1, Paola Lo Surdo1, Alessia Liguori1, Nathalie Norais1, Laura Santini1, Vega Masignani1, Mariagrazia Pizza1, Marzia Monica Giuliani2.   

Abstract

Neisseria adhesin A (NadA) is one of the antigens of Bexsero, the recently licensed multicomponent vaccine against serogroup B Neisseria meningitidis (MenB). NadA belongs to the class of oligomeric coiled-coil adhesins and is able to mediate adhesion and invasion of human epithelial cells. As a vaccine antigen, NadA has been shown to induce high levels of bactericidal antibodies; however, the domains important for protective response are still unknown. In order to further investigate its immunogenic properties, we have characterized the murine IgG1 mAb (6E3) that was able to recognize the 2 main antigenic variants of NadA on the surface of MenB strains. The epitope targeted by mAb 6E3 was mapped by hydrogen-deuterium exchange mass spectrometry and shown to be located on the coiled-coil stalk region of NadA (aa 206-249). Although no serum bactericidal activity was observed for murine IgG1 mAb 6E3, functional activity was restored when using chimeric antibodies in which the variable regions of the murine mAb 6E3 were fused to human IgG3 constant regions, thus confirming the protective nature of the mAb 6E3 epitope. The use of chimeric antibody molecules will enable future investigations of complement-mediated antibody functionality independently of the Fc-mediated differences in complement activation. © FASEB.

Entities:  

Keywords:  MenB vaccine; bactericidal epitope; epitope mapping; hydrogen-deuterium exchange; meningococcal antigen

Mesh:

Substances:

Year:  2015        PMID: 26304221     DOI: 10.1096/fj.15-273813

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Research advances in hydrogen-deuterium exchange mass spectrometry for protein epitope mapping.

Authors:  Haofeng Sun; Lingyun Ma; Leyu Wang; Peng Xiao; Hongmei Li; Min Zhou; Dewei Song
Journal:  Anal Bioanal Chem       Date:  2021-01-06       Impact factor: 4.142

2.  Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches.

Authors:  Guillaume Terral; Thierry Champion; François Debaene; Olivier Colas; Maxime Bourguet; Elsa Wagner-Rousset; Nathalie Corvaia; Alain Beck; Sarah Cianferani
Journal:  MAbs       Date:  2017-09-21       Impact factor: 5.857

3.  MEMHDX: an interactive tool to expedite the statistical validation and visualization of large HDX-MS datasets.

Authors:  Véronique Hourdel; Stevenn Volant; Darragh P O'Brien; Alexandre Chenal; Julia Chamot-Rooke; Marie-Agnès Dillies; Sébastien Brier
Journal:  Bioinformatics       Date:  2016-07-13       Impact factor: 6.937

Review 4.  Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination.

Authors:  Mariëlle C Haks; Barbara Bottazzi; Valentina Cecchinato; Corinne De Gregorio; Giuseppe Del Giudice; Stefan H E Kaufmann; Antonio Lanzavecchia; David J M Lewis; Jeroen Maertzdorf; Alberto Mantovani; Federica Sallusto; Marina Sironi; Mariagrazia Uguccioni; Tom H M Ottenhoff
Journal:  Front Immunol       Date:  2017-11-15       Impact factor: 7.561

5.  NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies.

Authors:  Alessia Liguori; Lucia Dello Iacono; Giulietta Maruggi; Barbara Benucci; Marcello Merola; Paola Lo Surdo; Jacinto López-Sagaseta; Mariagrazia Pizza; Enrico Malito; Matthew J Bottomley
Journal:  mBio       Date:  2018-10-16       Impact factor: 7.867

Review 6.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.

Authors:  Arno Thibau; Alexander A Dichter; Diana J Vaca; Dirk Linke; Adrian Goldman; Volkhard A J Kempf
Journal:  Med Microbiol Immunol       Date:  2019-12-01       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.